We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

By LabMedica International staff writers
Posted on 01 Aug 2025

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. More...

While immunotherapy, especially PD-1 protein blockade, has revolutionized treatment for advanced melanoma, 40% to 60% of patients do not respond effectively. This not only exposes them to significant side effects but also imposes a heavy financial burden. In countries like Brazil, this poses serious challenges to healthcare systems, creating a pressing need to identify which patients will benefit from immunotherapy and to avoid unnecessary costs and treatment failures. Researchers have now developed a precision tool that can predict immunotherapy treatment failure, with the potential to personalize therapies and reduce healthcare costs.

In the study led by the Molecular Oncology Research Center at Hospital de Amor (Barretos, Brazil), researchers analyzed tumor samples from 35 patients with advanced melanoma treated with anti-PD-1 immunotherapy between 2016 and 2021. The team cross-referenced these samples with a panel of 579 genes related to immune system function, ultimately identifying four genes — CD24, NFIL3, FN1, and KLRK1 — whose increased expression correlated with treatment resistance. These genes are involved in immune evasion and suppression of the inflammatory response. For instance, CD24 acts as an immune checkpoint, while FN1 supports tumor growth, KLRK1 loses its immune activation function when dysregulated, and NFIL3 contributes to tumor escape. The study utilized NanoString technology, a cost-effective and accessible genetic analysis platform suitable for clinical use in resource-limited settings. Notably, the genetic signature also showed predictive power for early-stage melanoma patients, indicating its usefulness from the beginning of treatment planning.

The findings, published in the Journal of Molecular Medicine, were validated against two international patient cohorts, where the gene expression signature consistently predicted both treatment response and clinical outcomes. According to the results, patients with high expression of the four genes were 230 times more likely to fail immunotherapy, with only 5.9% surviving after five years compared to 48.1% in those with low gene expression. The research team is now working on patenting a genetic panel based on this signature, with plans to develop a commercial tool that can guide treatment decisions before initiating immunotherapy. Despite the study's small size and retrospective nature, the findings mark a significant advancement in personalized oncology in Brazil. The next step involves conducting larger studies to define a gene expression threshold that can reliably predict treatment failure.

Related Links:
Hospital de Amor


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clinical Chemistry System
P780
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.